Vascular  	Vascular  	 NNP	B-NP
Accessibility  	Accessibility  	 NNP	I-NP
of  	of  	 IN	I-NP
Endothelial  	Endothelial  	 NNP	I-NP
Targeted  	Targeted  	 NNP	I-NP
Ferritin  	Ferritin  	 NNP	I-NP
Nanoparticles  	Nanoparticles  	 NNP	I-NP
Targeting  	Targeting  	 NNP	O
nanocarriers  	nanocarriers  	 VBD	O
to  	to  	 TO	O
the  	the  	 DT	O
endothelium 	endothelium 	 NN	B-NP
,  	,  	 ,	O
using  	using  	 VBG	O
affinity  	affinity  	 JJ	B-NP
ligands  	ligands  	 NN	I-NP
to  	to  	 TO	O
cell  	cell  	 VB	O
adhesion  	adhesion  	 JJ	O
molecules  	molecules  	 NNS	O
such  	such  	 JJ	O
as  	as  	 IN	O
ICAM-1  	ICAM-1  	 NNP	B-NP
and  	and  	 CC	O
PECAM-1 	PECAM-1 	 NNP	B-NP
,  	,  	 ,	O
holds  	holds  	 VBZ	O
promise  	promise  	 NN	O
to  	to  	 TO	O
improve  	improve  	 VB	O
the  	the  	 DT	O
pharmacotherapy  	pharmacotherapy  	 NN	B-NP
of  	of  	 IN	O
many  	many  	 JJ	O
disease  	disease  	 NN	B-NP
conditions 	conditions 	 NNS	I-NP
.  	.  	 .	O
This  	This  	 DT	O
approach  	approach  	 NN	O
capitalizes  	capitalizes  	 NN	O
on  	on  	 IN	O
the  	the  	 DT	O
observation  	observation  	 NN	O
that  	that  	 IN	O
antibody-targeted  	antibody-targeted  	 JJ	O
carriers  	carriers  	 NNS	O
of  	of  	 IN	O
100  	100  	 CD	O
nm  	nm  	 NNS	B-NP
and  	and  	 CC	O
above  	above  	 IN	O
accumulate  	accumulate  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
pulmonary  	pulmonary  	 JJ	B-NP
vasculature  	vasculature  	 NN	I-NP
more  	more  	 RBR	O
effectively  	effectively  	 RB	O
than  	than  	 IN	O
free  	free  	 JJ	O
antibodies 	antibodies 	 NNS	B-NP
.  	.  	 .	O
Targeting  	Targeting  	 VBG	O
of  	of  	 IN	O
prospective  	prospective  	 JJ	B-NP
nanocarriers  	nanocarriers  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
10-50  	10-50  	 JJ	O
nm  	nm  	 JJ	O
range 	range 	 NN	O
,  	,  	 ,	O
however 	however 	 RB	O
,  	,  	 ,	O
has  	has  	 VBZ	O
not  	not  	 RB	O
been  	been  	 VBN	O
studied 	studied 	 VBN	O
.  	.  	 .	O
To  	To  	 TO	O
address  	address  	 VB	O
this  	this  	 DT	O
intriguing  	intriguing  	 JJ	O
issue 	issue 	 NN	O
,  	,  	 ,	O
we  	we  	 PRP	O
conjugated  	conjugated  	 VBP	O
monoclonal  	monoclonal  	 JJ	B-NP
antibodies  	antibodies  	 NNS	I-NP
( 	( 	 -LRB-	O
Ab 	Ab 	 NNP	B-NP
)  	)  	 -RRB-	O
to  	to  	 TO	O
ICAM-1  	ICAM-1  	 CD	B-NP
and  	and  	 CC	O
PECAM-1  	PECAM-1  	 NNP	B-NP
or  	or  	 CC	O
their  	their  	 PRP$	O
single  	single  	 JJ	O
chain  	chain  	 NN	B-NP
antigen-binding  	antigen-binding  	 JJ	I-NP
fragments  	fragments  	 NNS	I-NP
( 	( 	 -LRB-	O
scFv 	scFv 	 NNP	B-NP
)  	)  	 -RRB-	O
to  	to  	 TO	O
ferritin  	ferritin  	 VB	B-NP
nanoparticles  	nanoparticles  	 NNS	I-NP
( 	( 	 -LRB-	O
FNPs 	FNPs 	 NNP	B-NP
,  	,  	 ,	O
size  	size  	 NN	O
12  	12  	 CD	O
nm 	nm 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
thereby  	thereby  	 RB	O
producing  	producing  	 VBG	B-NP
Ab 	Ab 	 NNP	I-NP
/ 	/ 	 NNP	I-NP
FNPs  	FNPs  	 NNP	I-NP
and  	and  	 CC	O
scFv 	scFv 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
FNPs 	FNPs 	 NNP	I-NP
.  	.  	 .	O
Targeted  	Targeted  	 NNP	B-NP
FNPs  	FNPs  	 NNP	I-NP
retained  	retained  	 VBD	O
their  	their  	 PRP$	O
typical  	typical  	 JJ	O
symmetric  	symmetric  	 JJ	B-NP
core-shell  	core-shell  	 JJ	I-NP
structure  	structure  	 NN	I-NP
with  	with  	 IN	O
sizes  	sizes  	 NNS	O
of  	of  	 IN	O
20-25  	20-25  	 CD	O
nm  	nm  	 NNS	B-NP
and  	and  	 CC	O
∼4-5  	∼4-5  	 NNP	O
Ab  	Ab  	 NNP	O
( 	( 	 -LRB-	O
or  	or  	 CC	O
∼7-9  	∼7-9  	 NNP	O
scFv 	scFv 	 NNP	O
)  	)  	 -RRB-	O
per  	per  	 FW	O
particle 	particle 	 FW	B-NP
.  	.  	 .	O
Ab 	Ab 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
FNPs  	FNPs  	 NNP	I-NP
and  	and  	 CC	O
scFv 	scFv 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
FNPs 	FNPs 	 NNP	I-NP
,  	,  	 ,	O
but  	but  	 CC	O
not  	not  	 RB	O
control  	control  	 VB	O
IgG 	IgG 	 JJ	O
/ 	/ 	 NNP	O
FNPs 	FNPs 	 NNP	O
,  	,  	 ,	O
bound  	bound  	 VBN	O
specifically  	specifically  	 RB	O
to  	to  	 TO	O
cells  	cells  	 NNS	O
expressing  	expressing  	 VBG	B-NP
target  	target  	 NN	I-NP
molecules  	molecules  	 NNS	I-NP
and  	and  	 CC	O
accumulated  	accumulated  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
lungs  	lungs  	 NNS	O
after  	after  	 IN	O
intravenous  	intravenous  	 JJ	B-NP
injection 	injection 	 NN	I-NP
,  	,  	 ,	O
with  	with  	 IN	O
pulmonary  	pulmonary  	 NNS	B-NP
targeting  	targeting  	 VBG	O
an  	an  	 DT	O
order  	order  	 NN	O
of  	of  	 IN	O
magnitude  	magnitude  	 NN	O
higher  	higher  	 JJR	O
than  	than  	 IN	O
free  	free  	 JJ	O
Ab 	Ab 	 NNP	B-NP
.  	.  	 .	O
Most  	Most  	 RBS	O
intriguing 	intriguing 	 JJ	O
,  	,  	 ,	O
the  	the  	 DT	O
targeting  	targeting  	 VBG	O
of  	of  	 IN	O
Ab 	Ab 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
FNPs  	FNPs  	 NNP	I-NP
to  	to  	 TO	O
ICAM-1 	ICAM-1 	 CD	B-NP
,  	,  	 ,	O
but  	but  	 CC	O
not  	not  	 RB	O
PECAM-1 	PECAM-1 	 CD	B-NP
,  	,  	 ,	O
surpassed  	surpassed  	 VBN	O
that  	that  	 IN	O
of  	of  	 IN	O
larger  	larger  	 JJR	O
Ab 	Ab 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
carriers  	carriers  	 NNS	I-NP
targeted  	targeted  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
same  	same  	 JJ	O
ligand 	ligand 	 NN	B-NP
.  	.  	 .	O
These  	These  	 DT	O
results  	results  	 NNS	O
indicate  	indicate  	 VBP	O
that  	that  	 IN	O
( 	( 	 -LRB-	O
i 	i 	 FW	O
)  	)  	 -RRB-	O
FNPs  	FNPs  	 NNP	B-NP
may  	may  	 MD	O
provide  	provide  	 VB	O
a  	a  	 DT	O
platform  	platform  	 NN	O
for  	for  	 IN	O
targeting  	targeting  	 VBG	O
endothelial  	endothelial  	 JJ	B-NP
adhesion  	adhesion  	 JJ	I-NP
molecules  	molecules  	 NNS	I-NP
with  	with  	 IN	O
carriers  	carriers  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
20  	20  	 CD	O
nm  	nm  	 JJ	B-NP
size  	size  	 NN	I-NP
range 	range 	 NN	I-NP
,  	,  	 ,	O
which  	which  	 WDT	O
has  	has  	 VBZ	O
not  	not  	 RB	O
been  	been  	 VBN	O
previously  	previously  	 RB	O
reported 	reported 	 VBD	O
;  	;  	 :	O
and  	and  	 CC	O
( 	( 	 -LRB-	O
ii 	ii 	 LS	O
)  	)  	 -RRB-	O
ICAM-1  	ICAM-1  	 NNP	B-NP
and  	and  	 CC	O
PECAM-1  	PECAM-1  	 NNP	B-NP
( 	( 	 -LRB-	O
known  	known  	 VBN	O
to  	to  	 TO	O
localize  	localize  	 VB	O
in  	in  	 IN	O
different  	different  	 JJ	O
domains  	domains  	 NN	O
of  	of  	 IN	O
endothelial  	endothelial  	 JJ	B-NP
plasmalemma 	plasmalemma 	 NN	I-NP
)  	)  	 -RRB-	O
differ  	differ  	 VBP	O
in  	in  	 IN	O
their  	their  	 PRP$	O
accessibility  	accessibility  	 NN	O
to  	to  	 TO	O
circulating  	circulating  	 VBG	B-NP
objects  	objects  	 NNS	I-NP
of  	of  	 IN	O
this  	this  	 DT	O
size 	size 	 NN	O
,  	,  	 ,	O
common  	common  	 JJ	O
for  	for  	 IN	O
blood  	blood  	 NN	O
components  	components  	 NNS	O
and  	and  	 CC	O
nanocarriers 	nanocarriers 	 NN	B-NP
.  	.  	 .	O
